Grubb N, Caldwell J, Strolin-Benedetti M
Department of Pharmacology and Toxicology, St. Mary's Hospital, London, U.K.
Biochem Pharmacol. 1993 Aug 17;46(4):759-61. doi: 10.1016/0006-2952(93)90565-e.
The excretion balance and the urinary metabolism of indobufen (+/- 2-[p-(1-oxo-2-isoindolinyl)-phenyl] butyric acid), a platelet aggregation inhibitor, has been studied in rats and mice after oral administration. The urinary metabolic profile of indobufen exhibited a marked species difference. The major metabolic pathway in the mouse was acyl glucuronidation followed by renal excretion, whereas in rats, 5-hydroxylation and subsequent sulphation at the introduced hydroxyl group predominated. Comparison of these results with previous data obtained in humans indicates that the mouse, and not the rat, is the rodent species of choice to be considered in the study of this compound.
